{
  "id": "71035c832a8c85ac",
  "title": "CMS ( 867 . HK / 8A8 . SG ): Ruxolitinib Phosphate Cream Obtained China NDA Approval , Becoming The First and Only Targeted Drug for Vitiligo in China \u2013 IT Business Net",
  "description": "[Skip to content](https://itbusinessnet.com/2026/01/cms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china/#content)\n",
  "content": "[Skip to content](https://itbusinessnet.com/2026/01/cms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china/#content)\n\n[Facebook](https://itbusinessnet.com/#facebook \"Facebook\") [Twitter](https://itbusinessnet.com/#twitter \"Twitter\") [LinkedIn](https://itbusinessnet.com/#linkedin \"LinkedIn\") [Email](https://itbusinessnet.com/#email \"Email\") [WhatsApp](https://itbusinessnet.com/#whatsapp \"WhatsApp\") [Flipboard](https://itbusinessnet.com/#flipboard \"Flipboard\") [Gmail](https://itbusinessnet.com/#google_gmail \"Gmail\") [X](https://itbusinessnet.com/#x \"X\") [Share](https://www.addtoany.com/share#url=https%3A%2F%2Fitbusinessnet.com%2F2026%2F01%2Fcms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china%2F&title=CMS%20(867.HK%2F8A8.SG)%3A%20Ruxolitinib%20Phosphate%20Cream%20Obtained%20China%20NDA%20Approval%2C%20Becoming%20The%20First%20and%20Only%20Targeted%20Drug%20for%20Vitiligo%20in%20China)\n\n![](https://itbusinessnet.com/wp-content/uploads/2026/01/CMS.jpg)\n\n**SHENZHEN, Jan 30, 2026 \u2013 (ACN Newswire) \u2013**\u00a0China Medical System Holdings Limited (\u201cCMS\u201d or the \u201cGroup\u201d) is pleased to announce that its subsidiary, Dermavon Holdings Limited (\u201cDermavon\u201d, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the \u201cProduct\u201d) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.",
  "source": "itbusinessnet.com",
  "source_url": "https://itbusinessnet.com/2026/01/cms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china/",
  "published_at": "20260131T134500Z",
  "fetched_at": "2026-02-01T00:32:37.375926+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "ai",
    "china"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://itbusinessnet.com/2026/01/cms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china/",
    "url_mobile": "https://itbusinessnet.com/2026/01/cms-867-hk-8a8-sg-ruxolitinib-phosphate-cream-obtained-china-nda-approval-becoming-the-first-and-only-targeted-drug-for-vitiligo-in-china/amp/",
    "title": "CMS ( 867 . HK / 8A8 . SG ): Ruxolitinib Phosphate Cream Obtained China NDA Approval , Becoming The First and Only Targeted Drug for Vitiligo in China \u2013 IT Business Net",
    "seendate": "20260131T134500Z",
    "socialimage": "",
    "domain": "itbusinessnet.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}